Literature DB >> 25275018

Chemotherapy of rare skin adnexal tumors: a review of literature.

Francesca De Iuliis1, Lucrezia Amoroso2, Ludovica Taglieri1, Stefania Vendittozzi2, Luciana Blasi2, Gerardo Salerno1, Rosina Lanza3, Susanna Scarpa4.   

Abstract

Malignant skin adnexal tumors are rare neoplasms which are derived from adnexal epithelial structures of the skin: hair follicle, or sebaceous, apocrine or eccrine glands. Among them, eccrine porocarcinoma is the most frequent, with an aggressive behavior compared to other more common forms of non-melanoma skin cancer. Only few reports describe the treatment of metastatic adnexal tumors, and there is no consensus about the better strategy of chemotherapy. Given the few cases and the absence of randomized clinical trials, it is important to collect clinical experiences on these tumors. Most of these adenocarcinomas are very aggressive and also chemoresistant, and only a targeted-therapy could have an impact on patient survival. Therefore, further studies on the biology of these diseases are necessary. The purpose of the present review is to discuss the treatment of malignant neoplasms of cutaneous adnexae and to suggest some future therapeutic options based on targeted-therapy. Copyright
© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Non-melanoma skin cancer; chemotherapy; eccrine cancer; metastasis; porocarcinoma; review; skin adnexal tumors; targeted therapy

Mesh:

Substances:

Year:  2014        PMID: 25275018

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Management of brain metastasis from eccrine porocarcinoma: illustrative case.

Authors:  Ryuichi Noda; Tomohiro Inoue; Sho Tsunoda; Masafumi Segawa; Yoshio Masuda; Teppei Morikawa; Atsuya Akabane
Journal:  J Neurosurg Case Lessons       Date:  2021-06-28

Review 2.  Current Treatment Options for Cutaneous Adnexal Malignancies.

Authors:  Hiroyuki Goto
Journal:  Curr Treat Options Oncol       Date:  2022-03-26

3.  Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.

Authors:  Rami Mäkelä; Ville Härmä; Nibal Badra Fajardo; Greg Wells; Zoi Lygerou; Olle Sangfelt; Juha Kononen; Juha K Rantala
Journal:  Oncotarget       Date:  2021-05-25

4.  Head and Neck Porocarcinoma: SEER Analysis of Epidemiology and Survival.

Authors:  Matteo Scampa; Rastine Merat; Daniel F Kalbermatten; Carlo M Oranges
Journal:  J Clin Med       Date:  2022-04-14       Impact factor: 4.964

5.  Metastatic Eccrine Porocarcinoma: A Rare Case of Successful Treatment.

Authors:  Hiren Mandaliya; Ina Nordman
Journal:  Case Rep Oncol       Date:  2016-08-17

6.  Metastatic adnexal cancer in a man.

Authors:  Rashmi Advani; Manhal Izzy; Ashwin Akki; Calley Levine; Nicole Panarelli; Lawrence J Brandt
Journal:  Ann Gastroenterol       Date:  2017-05-12

7.  Malignant adnexal tumors of the skin: a single institution experience.

Authors:  Tolutope Oyasiji; Wei Tan; John Kane; Joseph Skitzki; Valerie Francescutti; Kilian Salerno; Nikhil I Khushalani
Journal:  World J Surg Oncol       Date:  2018-05-30       Impact factor: 2.754

8.  Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective.

Authors:  Marcin Kleibert; Iga Płachta; Anna M Czarnecka; Mateusz J Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

Review 9.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

10.  Eccrine Porocarcinoma: A Challenging Diagnostic and Therapeutic Tumoral Entity.

Authors:  Ha Mo Linh Le; Laurence Faugeras; Véronique De Moor; Caroline Fervaille; Thierry Vander Borght; Fanny Collette; Lionel D'Hondt
Journal:  Case Rep Oncol       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.